GeneMail | Daily News of the Digital Life and Health Industry [Today's Headlines] 1. "Research on the Prevention and Control of Major Birth Defects" Key Special Fund received 480 million yuan in funding Keywords: Ministry of Science and Technology Reproductive Health On July 6, t

GeneMail | Daily News for Digital Life and Health Industry

[Today's Headlines]

1. "Research on Prevention and Control of Major Birth Defects" key special fund received 480 million yuan in funding

Keywords: Ministry of Science and Technology Reproductive Health

htmlOn July 6, the official website of the Ministry of Science and Technology released the 2018 annual project application guide for 12 key special projects. Among them, the "Research on the Prevention and Control of Reproductive Health and Major Birth Deficiencies" Key Special Project (Supplement Task) 2018 Annual Application Guide" focuses on reproductive health-related diseases, birth defects and assisted reproductive technologies; carry out scientific research aimed at revealing the main factors affecting human reproduction, early life development, and pregnancy outcomes; achieve a number of key technological breakthroughs such as screening and blocking of genetic defect diseases; and establish a comprehensive prevention and treatment demonstration application platform for early warning, early screening, diagnosis and treatment of reproductive health-related diseases that are suitable for Chinese people and are economical and effective. has added new basic research projects on reproductive laws and reproductive theory. In 2018, 20 research directions will be deployed, with the total estimated fund allocation of about 480 million yuan, and the implementation cycle will be from 2018 to 2021.

"Reproductive Health and Major Birth Defects Prevention and Control Research" Key Special Project (Supplement Task) 2018 Annual Project Application Guide" document Please log in to YourMap (yourmap.net.cn), a subsidiary of Genehui, click "Knowledge Base", and search for "Reproductive Health" to download.

[Toutiao Comments] 2017 "Research on Reproductive Health and Major Birth Defects Prevention and Control" has a total of 11 projects, with a total funding of about 166 million yuan. The funding has increased by nearly 2 times this year, and we are paying more attention to basic research. Previously, the National Health Commission released a list of 340 medical institutions approved for prenatal diagnosis (details). The distribution of institutions between provinces varies greatly. Strengthening basic research can be parallel to strengthening the infrastructure and medical capabilities of medical institutions, so as to truly alleviate birth defects and improve reproductive health.

2. Expert consensus: Application of NGS in precision medicine diagnosis of tumor

Keywords: Expert consensus NGS

htmlOn July 10, the Chinese Journal of Medicine published online entitled "Expert Consensus on the Application of Second Generation Sequencing Technology in Precision Medicine Diagnosis of Oncology". The main authors include Professor Zhang Xuchao of Guangdong Lung Cancer Research Institute, Professor Liang Zhiyong of the Department of Pathology of Peking Union Medical College Hospital, Professor Wang Shengyue of the National Translational Medicine Center of Ruijin Hospital, Shanghai Jiaotong University, Professor Lu Shun of the Pulmonary Medicine Oncology Center of the Chest Hospital Affiliated to Shanghai Jiaotong University, Professor Wu Yilong of the Tumor Diagnosis and Treatment Center of Guangdong People's Hospital, etc. This expert consensus elaborates on the quality requirements of NGS technology, clinical tumor-related NGS testing content, sample processing, sequencing process, data management, informatics analysis, result report interpretation and consultation.

Consensus original text, please log in to YourMap (yourmap.net.cn), a subsidiary of Genehui, click "Knowledge Base", search for "Expert Consensus" to download.

[Toutiao Comments] Previously, the expert consensus on "Next-generation sequencing technology detection process standards for breast cancer susceptible genes" was released (details), and in May, the "Expert Consensus on Genetic Diagnosis/Screening Technology of Preimplantation" was released (details). In March, the first expert consensus on clinical genetic testing report standards participated by Gene Hui was released, and consensus and standards are gradually being established in the field of genetic testing. The industry has gone through the early era of discussing the significance of genetic testing. In recent years, it has mainly focused on how to establish and unify standards. The next step may be to enhance the clinical service system and improve the process. A large number of clinical experts participated in the establishment of this consensus. As the main body of implementing genetic testing, clinical experts should be more familiar with genetic testing and participate in the establishment of standards.

[Scientific Research]

3. "Nature": 550,000 genetic data machine learning model predicts leukemia

Keywords: Leukemia Machine Learning

July 10, "Nature" published the latest results of cooperative research from multiple scientific research institutions around the world. By using blood detection and machine learning technology, healthy individuals are predicted whether they have the risk of acute myeloid leukemia (AML).This study tracked data from 550,000 people over 20 years and compared blood samples of patients and healthy people. applied machine learning technology to build an AML prediction model based on conventional recording variables in electronic health records. This model was able to predict AML within 6-12 months before diagnosis, with sensitivity and specificity reaching 25.7% and 98.2%, respectively, and its performance in different age groups was consistent. The model can detect the cause of leukemia five years in advance.

4. Cross-species horizontal gene transfer is widely present in eukaryotes

Keywords: Horizontal gene transfer Transposon

is different from the vertical transmission of genetic information in family lines, bacteria can horizontally exchange genes encoding antibiotic resistance. A new study by the University of Adelaide research team found that horizontal gene transfer occurs more widely and is found in eukaryotes in large quantities. The research results were published in Genome Biology on July 10. It is proposed that LINE-1 (L1) and Bovine-B (BovB) are the two most abundant retrotransposon families in mammals and are also present in many other species, such as reptiles, fish, etc. Cross-species-level gene transfer between plants and animals often occurs throughout the evolution, and a variety of possible L1-level gene transfer events were identified in eukaryotic species . Horizontal gene transfer may have a long-term impact on genome changes, and this study provides certain resources for large-scale genomic information level transfer research.

5. Two common substances kill senescent cells and extend the lifespan of mice by 36%

Keywords: Anti-aging

July 10 published a study by Nature Medicine. A new study found that two common substances can significantly prolong the lives of animals and significantly slow down their aging symptoms. A team from the Mayo Clinic found that even a small amount of senescent cells would be injected into young and healthy mice, it could lead to physical deterioration. Further research has found that combined treatment of dasatinib (a drug approved for market for leukemia in 2006) and quercetin (a substance rich in tea) can specifically kill senescent cells without affecting normal cells, delaying body function decline, and prolonging their lifespan. The study tried both drugs in mice 24-27 months old (equivalent to about 90 years of age in humans), and after treatment, the lifespan of mice could be increased by 36%.

[Policy]

6. The "Technical Guidance Principles for Accepting Overseas Clinical Trial Data of Drugs" was released to accelerate the launch of drugs in China

Keywords: Overseas Clinical Trials

On July 10, the State Administration for Drugs issued the "Technical Guidance Principles for Accepting Overseas Clinical Trial Data of Drugs". These guidelines apply to various registration applications for drugs with existing overseas clinical trial data within the territory of the People's Republic of China. clearly defines the scope of application, basic principles, completeness requirements, technical requirements for data submission and acceptance of overseas clinical trial data. As more and more multinational companies and domestic companies conduct international multi-center clinical trials to support global registration applications, synchronous research and development of drugs at home and abroad can reduce unnecessary duplicate research. This guiding principle aims to accelerate the process of drug marketed in China and better meet patients' medication needs.

file original text, please log in to YourMap (yourmap.net.cn), a subsidiary of Genehui, click "Knowledge Base", search for "Overseas Clinical Trials" to download.

[Industry]

7. Tianyan Pharmaceutical's new anti-tumor agonistic antibody drug has been approved by the FDA Clinical trial

Keywords: Tianyan Pharmaceutical's new antibody drug

Tumor immunity and targeted therapy developer Tianyan Pharmaceutical announced on July 10 that FDA approved one of its new drugs to conduct drug clinical trials. The agonistic antibody drug code-named ADG106 is approved to treat advanced solid tumors and non-Hodgkin's lymphoma.ADG-106 targets a unique target of CD137. CD137 (or 4-1BB) as a member of the tumor necrosis factor (TNF) receptor superfamily, is a clinically proven important pathway to effectively stimulate CAR-T cell proliferation. This target has important regulatory functions in CD8+ T cells, DC cells and natural killer (NK) cells, and has always been a highly concerned target in the fields of tumors and autoimmunity.

8. The first innovative drug for liver cancer has been qualified for FDA orphan drugs, and has accelerated the approval process

Keywords: OBI Pharma Anti-cancer drug

July 10, Taiwan, China, announced that its new anti-cancer drug OBI-3424 has been qualified for orphan drugs granted by the US FDA to accelerate the drug review process. The drug is used to treat hepatocellular carcinoma (HCC). OBI-3424 is a DNA alkylated cancer treatment drug with the target of overexpressing aldehyde ketone reductase 1C3 (AKR1C3). The Phase 1/2 study of in patients with solid tumors, including HCC and CRPC, has begun enrollment at the University of Texas MD Anderson Cancer Center.

9. BGI Intelligent Manufacturing launched the "Sequencer Plan" to provide the industry with a sequencing platform

Keywords: BGI Intelligent Manufacturing Sequencer

7 On July 8, at the second Genetic Testing and Health Industry Conference, the "Sequencer Plan" initiated by BGI Intelligent Manufacturing, Beijing Hope Group, Kangwei Century, Yuanma Gene, Aiji Taikang, Top Gene, Youle Reshen, and Byer Walker responded to it was officially launched. The program will provide an open cooperation platform for sequencing globally. The development of genetic testing and health industries requires platforms and tools. BGI Intelligent Manufacturing’s “Sequencer Program” will provide independent and controllable sequencing platforms and resources to the global sequencing industry, including reagents and consumables, technical support and joint market promotion.

10. Carbon Cloud Wangjun Holdings, microbiome company AOBiome applies for listing in Hong Kong

Keywords: AOBiome Listing

July 3, AOBiome Therapeutics (AOBiome for short) submitted listing application materials in Hong Kong, and the joint sponsors are Citigroup and Haitong International. AOBiome is the world's leading clinical stage microbiome company, focusing on the research and development of the treatment of inflammation, central nervous system disorders and other systemic diseases. In June 2018, Wang Jun, founder of Carbon Cloud Intelligent, became the chairman of the company's board of directors. Nearly three years after Carbon Cloud Intelligent was founded, Carbon Cloud will soon usher in its first listed company.

Scan the code to add WeChat and enter the reader group

(please indicate: name, unit, position, purpose of coming)

[More in-depth articles]

• [Industry research] 2018 Gene Industry Venture Capital Report Ten Years of Industrialization of Gene Sequencing Technology 15 listed companies Q1 financial report
• [Professional Conference ] Industry's first private board Gene Detection Alliance Preparatory Committee Genetic Disease Branch of Guangdong Precision Medicine Applied Society
• [Three People] Clinical Gene Detection Biological Cloud Platform Microbiome Gene Health Management Tumor Precision Medicine
• [Big Names on Health] 14 Precision Medicine Big Names 33 Industry Pioneers Interview 27 Clinical Gene Detection Big Names
• [Star of Tomorrow] Counsyl DNAnexus Verily Helix

[About Gene Hui] Gene Hui is a professional science and technology media and consulting institution in the field of digital life and health. Based on the professionalism of ten years of deep cultivation, we are committed to establishing a big data platform for industry credit rating and decision-making consultation, providing popular science publicity, industry research consultation and industry link services to medical and health institutions, empowering the integration of industry, academia and government, making connections generate value and using data to make the future.

Gene Hui, as the editorial unit of the "Exploration and Practice of Clinical Biological Sample Library" key book "The 13th Five-Year Plan", the Standing Committee of the Genetic Disease Branch of the Guangdong Precision Medicine Society and the Vice President of the Shenzhen Health Industry Development Promotion Association, released several reports (details) such as the "2018 Gene Industry Venture Capital Report" at the industry conference, participated in the implementation of the first "Clinical Gene Test Report Standards and Genetic Test Industry Consensus" (details), and hosted the first Digital Health Private Board of Directors (details), providing industry consulting and market research services to governments and industry decision makers.

Contact us: www.yourmap.net.cn, 400-088-7466, [email protected]